Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions. A separate ranking incorporating additional characteristics showed that effectiveness in treating multiple manifestations of psoriatic disease was also important The number of injections per dose and injection frequency were least important to patients according to the ranking analysis Basel, September 12, 2018 - Novartis, a leader in immuno-dermatology, announced today new data from a patient preference survey showing psoriasis patients want their treatment to go beyond just clear skin and safety. This study of 300 psoriasis patients is being presented during a poster session at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. Results confirmed that clear skin is the most preferred treatment attribute, which is consistent with previous patient preference surveys in psoriasis - . Results also show patients expect additional benefits from their treatment that are not traditionally assessed in patient surveys, including the number of years of proven efficacy and safety data in large clinical trials and no injection site reactions. In a separate ranking incorporating additional characteristics, patients ranked the effectiveness in treating multiple manifestations of psoriatic disease (including PsA, nail, palmoplantar and scalp), and complete symptom relief, as being important, after risk of side effects and clear skin (including time to achieve clear skin) .
